All CATEGORIES
☰ Menu

FDA approves brain imaging tool for Alzheimer’s

Associated Press

WASHINGTON: The Food and Drug Administration has approved a radioactive imaging chemical from General Electric to help screen for Alzheimer’s disease.

The drug, Vizamyl, is an injection of radioactive material designed to highlight abnormal brain plaque in medical imaging scans.

Dementia caused by Alzheimer’s is associated with buildup of the plaque, known as beta amyloid protein. However, it can also be found in patients who do not have neurological problems.

Vizamyl works by binding to the plaque and creating images that show up on positron emission tomography, or PET, scans of the brain.

The FDA says a negative scan means there is little plaque and the cause of dementia is probably not Alzheimer’s. A positive scan means the patient has at least some plaque, but does not prove they have Alzheimer’s.



MORE IN LIFESTYLE

 
  • Main Blog Promo
  • Cavs Blog Promo
  • Browns Blog Promo
  • Indians Blog Promo
  • Beer Blog Promo
  • Fracking Blog Promo
  • Entertainment Blog Promo
  • High School Blog Promo
  • Zips Blog Promo
  • Akron Dish Food Blog
Prev Next